Latest news with #OneHealthMission
Time of India
25-04-2025
- Health
- Time of India
Scientists achieve breakthrough in gene therapy for haemophilia
Bengaluru: The country's first human gene therapy trial for haemophilia was conducted through a collaboration between Biotechnology Research and Innovation Council's Institute for Stem Cell Science and Regenerative Medicine ( BRIC-inStem ) in Bengaluru and CMC Vellore, officials announced Thursday. Haemophilia is a genetic blood disorder where blood doesn't clot normally, causing abnormal bleeding. You Can Also Check: Bengaluru AQI | Weather in Bengaluru | Bank Holidays in Bengaluru | Public Holidays in Bengaluru Union science and technology minister Jitendra Singh reviewed the progress during an inspection of facilities at BRIC-inStem. "This is a milestone in India's scientific journey," Singh said, highlighting the institute's contributions to preventive and regenerative healthcare. "This is not just about science, it's about nation-building," he said. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Secure Your Child's Future with Strong English Fluency Planet Spark Learn More Undo The minister stressed the importance of biotechnology in shaping India's economy and public health infrastructure. "India's biotechnology sector experienced remarkable growth, expanding 16-fold over the past decade to reach $165.7 billion in 2024, with projections of $300 billion by 2030," an official statement read. Singh attributed this growth to policy reforms, including the recently approved BIO-E3 policy designed to boost economy, employment and environment through biotechnology. "We now have over 10,000 biotech startups compared to just 50 a decade ago," he said. Singh toured BRIC-inStem's Biosafety Level III laboratory, a critical national facility for studying high-risk pathogens under India's One Health Mission. "The pandemic taught us that we must always be prepared. Facilities like this will help us stay a step ahead," Singh said. The newly launched Centre for Research Application and Training in Embryology (CReATE) received praise for its work on addressing birth defects and infertility through developmental biology research. "With 3% to 4% of babies born with some form of defect, this centre is vital for improving maternal and neonatal health outcomes," the minister said. Calling for greater collaboration between scientific and medical institutions, Singh suggested that BRIC-inStem explore MD-PhD programmes and strengthen integration with clinical research. "As Mark Twain said, the economy is too serious a subject to be left to economists alone. Biotechnology is not just a science anymore — it is a pillar of our national strategy," Singh said.
New Indian Express
25-04-2025
- Health
- New Indian Express
‘Biotech shaping future economy, public health': Union Minister Jitendra Singh
BENGALURU: Union Minister of State for Science and Technology and Earth Sciences Jitendra Singh on Thursday emphasised the role of biotechnology in shaping India's future economy and public health. Dr Singh, who inspected the Biotechnology Research and Innovation Council -- Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem), a research institute under the Department of Biotechnology, Ministry of Science and Technology, described the sector's contribution as pivotal for nation-building. 'This is not just about science, it's about nation-building,' he said and lauded the Department of Biotechnology (DBT) for its achievements and transformation from a relatively obscure sector to a national powerhouse. The minister inspected the facilities and reviewed clinical trials, including the first-in-human gene therapy trial for haemophilia, conducted in collaboration with CMC, Vellore, at the institute. Stating that India's biotechnology industry is witnessing a remarkable growth, Dr Singh said it has expanded 16-fold over the past decade to reach $165.7 billion in 2024, with a target of $300 billion by 2030. Dr Singh attributed this progress to policy reforms such as the BIO-E3 Policy, designed to boost the economy, create jobs, and improve environmental sustainability. 'The country now boasts of having over 10,000 biotech startups, an increase from just 50 a decade ago,' he added. He visited BRIC-inStem's Biosafety Level III Laboratory, which serves as a critical facility for studying high-risk pathogens under India's One Health Mission. The Union minister also visited the new Centre for Research Application and Training in Embryology (CReATE), which focuses on addressing birth defects and infertility through research. He highlighted its vital role in improving maternal and neonatal health outcomes, noting that approximately 3 to 4% of babies are born with some defects. Dr Singh stressed the need for increased collaboration between scientific and medical institutions and suggested that BRIC-inStem should explore MD-Ph.D programmes, strengthen ties with clinical research, and enhance its visibility through coordinated communication. What's being done here should echo across the country. It's not just for publicity, the nation needs it, he said.
Time of India
25-04-2025
- Health
- Time of India
India conducts first human gene therapy trial for haemophilia
Bengaluru: A collaboration between Biotechnology Research and Innovation Council's Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem) in Bengaluru and CMC Vellore has resulted in the country's first human gene therapy trial for haemophilia, officials announced on Thursday. Haemophilia is a genetic blood disorder in which blood doesn't clot normally, causing abnormal bleeding. Union science and technology minister Jitendra Singh reviewed progress in the work during an inspection of facilities at BRIC-inStem. "This is a milestone in India's scientific journey," he said, highlighting the institute's contributions to preventive and regenerative healthcare. Singh toured BRIC-inStem's Biosafety Level III laboratory, a critical national facility for studying high-risk pathogens under India's One Health Mission. "The pandemic taught us that we must always be prepared. Facilities like this will keep us ahead of hazards." The newly launched Centre for Research Application and Training in Embryology (CReATE) came in for praise for its work on addressing birth defects and infertility through developmental biology research.
